A5050243008- Neuroendocrine Tumor Research Advances
- Sarcoma Diagnosis and Treatment
- Bone health and treatments
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Glioma Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging and Pathology Studies
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Bone Tumor Diagnosis and Treatments
- Management of metastatic bone disease
- Bone Metabolism and Diseases
- Medical Imaging Techniques and Applications
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- 3D Printing in Biomedical Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Oral and Maxillofacial Pathology
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2015-2025
Istituto Ortopedico Rizzoli
2022-2025
Media Working Group
2024
University of New Haven
2024
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2023
University of Bologna
2021-2022
Istituto Oncologico Veneto
2021
Ain Shams University
2020
University of Palermo
2020
Institut Gustave Roussy
2018
This analysis was performed to further characterise treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab.Laboratory abnormalities and adverse events of metastatic disease were analysed using data from three identically designed phase 3 trials subcutaneous denosumab 120 mg (n = 2841) versus intravenous zoledronic acid 4 2836).The overall incidence laboratory grade ⩾ 2 higher (12.4%) than (5.3%). Hypocalcaemia primarily severity usually occurred within the...
Abstract We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence metastasis were collected statistically analyzed. Bone metastases evident at diagnosis 57.5% patients. In remaining cases median time appearance was 9 months. Biphosphonates administered 59.6% Skeletal-related events experienced by...
<h3>Objective</h3> Although adjuvant trastuzumab improves survival in patients with HER2-positive early breast cancer, there is growing concern about the long-term effect of trastuzumab-induced cardiotoxicity (TIC). We retrospectively assessed incidence TIC and heart failure (HF) to identify possible risk protective factors. <h3>Design</h3> Retrospective study. <h3>Setting</h3> Institute for Cancer Research Treatment, Medical Oncology Department. <h3>Patients</h3> Consecutive who started...
Bone metastasis is a complex process that needs to be better understood in order help clinicians prevent and treat it. Xenografts using patient-derived material (PDX) rather than cancer cell lines are novel approach guarantees more clinically realistic results. A primary culture of bone derived from 67-year-old patient with breast was cultured then injected into zebrafish (ZF) embryos study its metastatic potential. In vivo behavior results gene expression analyses the were compared those...
PURPOSE Approved systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown limited capacity to reduce tumor burden and no antitumor activity after progression targeted agents (TAs). We investigated the efficacy safety of lenvatinib in patients with previously treated GEP-NETs. PATIENTS AND METHODS This was a multicenter, single-arm, open-label, phase II trial two parallel cohorts (ClinicalTrials.gov identifier: NCT02678780 ) involving 21 institutions...
<h3>Importance</h3> Data about the optimal timing for initiation of peptide receptor radionuclide therapy (PRRT) advanced, well-differentiated enteropancreatic neuroendocrine tumors are lacking. <h3>Objective</h3> To evaluate association upfront PRRT vs chemotherapy or targeted with progression-free survival (PFS) among patients advanced who experienced disease progression after treatment somatostatin analogues (SSAs). <h3>Design, Setting, and Participants</h3> This retrospective,...
Giant cell tumor of bone (GCTB) and desmoplastic fibroma (DF) are sarcomas with intermediate malignant behavior unpredictable prognosis. These locally aggressive neoplasms exhibit a predilection for the long or mandible young adults, causing severe resorption. In particular, stromal cells these lesions responsible recruiting multinucleated giant which ultimately lead to disruption. this regard, underlying pathological mechanism osteoclastogenesis processes in GCTB DF is still poorly...
A second-line standard of treatment has not yet been identified in patients with soft tissue sarcomas (STS), so identifying predictive markers could be a valuable tool. Recent studies have shown that the intratumoral and inflammatory systems significantly influence tumor aggressiveness. We aimed to investigate prognostic values pre-therapy neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR), lymphocyte-to-monocyte (LMR), systemic index (SII), progression-free survival (PFS),...
Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease RCC.Data clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence were statistically analyzed.Median time to was 25 months without at diagnosis. Median diagnosis by MSKCC risk 24 good, 5 intermediate, 0...
Aim of this study was to investigate for the presence existing prognostic factors in patients with bone metastases (BMs) from RCC since represents an unfavorable site metastasis renal cell carcinoma (mRCC). Data BMs were retrospectively collected. Age, sex, ECOG-Performance Status (PS), MSKCC group, tumor histology, concomitant other sites, time nephrectomy (TTBM, classified into three groups: <1 year, between 1 and 5 years >5 years) skeletal-related event (SRE) included Cox analysis their...